ReviewClinics in laboratory medicine2009
Respiratory syncytial virus vaccine development.
Review in Clinics in laboratory medicine, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Article
- Priorities for developing respiratory syncytial virus vaccines in different target populations.Science translational medicine · 2020Review
- Development of respiratory syncytial virus (RSV) vaccines for infants.The Journal of infection · 2017Review
- Human CD8(+) T Cells Target Multiple Epitopes in Respiratory Syncytial Virus Polymerase.Viral immunology · 2016Article
- Antiviral effect of emodin from Rheum palmatum against coxsakievirus B5 and human respiratory syncytial virus in vitro.Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban · 2015Article
- Biomarkers of respiratory syncytial virus (RSV) infection: specific neutrophil and cytokine levels provide increased accuracy in predicting disease severity.Paediatric respiratory reviews · 2015Review
- Immunological, Viral, Environmental, and Individual Factors Modulating Lung Immune Response to Respiratory Syncytial Virus.BioMed research international · 2015Review
- Respiratory syncytial virus infections in infants affected by primary immunodeficiency.Journal of immunology research · 2014Review
- Respiratory syncytial virus--a comprehensive review.Clinical reviews in allergy & immunology · 2013Review
- The epidemiology and clinical characteristics of young children hospitalized with respiratory syncytial virus infections in Guatemala (2007-2010).The Pediatric infectious disease journal · 2013Article
- An adjuvanted respiratory syncytial virus fusion protein induces protection in aged BALB/c mice.Immunity & ageing : I & A · 2012Article
- The human respiratory syncytial virus nonstructural protein 1 regulates type I and type II interferon pathways.Molecular & cellular proteomics : MCP · 2012Article
- Article
- Article
- Replacement of previously circulating respiratory syncytial virus subtype B strains with the BA genotype in South Africa.Journal of virology · 2011Article
- Vaccinomics and a new paradigm for the development of preventive vaccines against viral infections.Omics : a journal of integrative biology · 2011Review
- Respiratory syncytial virus prevention in children with congenital heart disease: who and how?Korean journal of pediatrics · 2011Article
- An evaluation of the emerging interventions against Respiratory Syncytial Virus (RSV)-associated acute lower respiratory infections in children.BMC public health · 2011Review
- A highly attenuated recombinant human respiratory syncytial virus lacking the G protein induces long-lasting protection in cotton rats.Virology journal · 2010Article
- A decade of respiratory syncytial virus epidemiology and prophylaxis: translating evidence into everyday clinical practice.Canadian respiratory journalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Respiratory syncytial virus (RSV) is a clinically significant cause of respiratory tract disease, especially among high-risk infants and immunocompromised and elderly adults. Despite the burden of disease, there is no licensed prophylactic RSV vaccine. The initial efforts to develop an RSV vaccine involved formalin-inactivated virus preparations that unexpectedly caused vaccine-enhanced disease in clinical trials in RSV-naive children. Over the last 40 years, cautious and deliberate progress has been made toward RSV vaccine development using various experimental approaches, including live attenuated strains and vector-based and viral protein subunit/DNA-based candidates. The scientific rationale, preclinical testing, and clinical development of each of these approaches are reviewed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.